Esomeprazole

How to order Esomeprazole

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Esomeprazole on Prescriptsy

Esomeprazole is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Esomeprazole is a proton pump inhibitor (PPI) used to treat conditions caused by excess stomach acid, including gastro-oesophageal reflux disease (GORD), peptic ulcers and Helicobacter pylori infection.

It is one of the most commonly prescribed medicines in the UK and works by irreversibly blocking the proton pump in the stomach lining, reducing acid production by approximately 80 to 90%.

Esomeprazole is available as 20 mg and 40 mg tablets and capsules.

It is the S-isomer of omeprazole and is marketed under brand names including Nexium, though generic esomeprazole is now widely used.

Higher doses are prescription-only (POM), while esomeprazole 20 mg is available as a pharmacy (P) medicine for short-term heartburn relief.

Gastro-oesophageal reflux disease is one of the most prevalent gastrointestinal conditions in the Western world, affecting an estimated 10 to 20% of the UK adult population.

It occurs when acidic stomach contents reflux into the oesophagus, causing symptoms such as heartburn (a burning sensation behind the breastbone), acid regurgitation, chest pain, difficulty swallowing and a sour taste in the mouth.

Persistent, untreated reflux can lead to erosive oesophagitis, oesophageal stricture, Barrett's oesophagus (a pre-cancerous change in the oesophageal lining) and, rarely, oesophageal adenocarcinoma.

Effective acid suppression with a PPI is the cornerstone of GORD treatment.

This page provides a comprehensive clinical overview of esomeprazole, including its mechanism of action, indications, dosing guidance, expected benefits, potential side effects, important safety warnings and how to access treatment in the United Kingdom.

Important safety information about esomeprazole

Before reading further, note these essential safety points.

• Esomeprazole at 40 mg is a prescription-only medicine; 20 mg is available from pharmacies for short-term use.
• Do not take esomeprazole for more than 2 weeks without medical advice if self-treating for heartburn.
• Seek urgent medical advice if you have alarm symptoms: difficulty swallowing, unexplained weight loss, vomiting blood, or passing black stools.
• Long-term PPI use should be reviewed regularly by your GP to ensure the lowest effective dose is used.
• Tell your prescriber about all other medicines you take, especially clopidogrel, methotrexate and HIV medicines.

Understanding gastro-oesophageal reflux disease

The lower oesophageal sphincter (LOS) is a ring of muscle at the junction of the oesophagus and stomach.

It normally relaxes during swallowing to allow food into the stomach and then closes to prevent gastric contents from refluxing upward.

In GORD, the LOS relaxes inappropriately or is weakened, allowing acidic stomach contents to flow back into the oesophagus.

The oesophageal mucosa is not designed to withstand prolonged exposure to gastric acid (pH 1 to 3), and repeated reflux causes inflammation, erosion and symptoms.

Risk factors for GORD include obesity (increased intra-abdominal pressure), hiatus hernia (displacement of the gastro-oesophageal junction through the diaphragm), pregnancy, smoking, certain foods and drinks (fatty food, chocolate, coffee, alcohol, citrus, tomatoes), certain medicines (NSAIDs, calcium channel blockers, bisphosphonates) and stress.

NICE clinical knowledge summaries recommend lifestyle modifications as the first step, including weight loss if overweight, elevating the head of the bed, avoiding eating within 3 hours of bedtime, and reducing trigger foods.

When lifestyle measures are insufficient, acid suppression therapy with a PPI is recommended.

How esomeprazole works: mechanism of action

Gastric acid is produced by parietal cells in the stomach lining.

The final step of acid secretion is mediated by the hydrogen-potassium ATPase enzyme, commonly known as the proton pump.

This enzyme actively transports hydrogen ions into the stomach lumen in exchange for potassium ions, generating the highly acidic gastric juice needed for digestion and sterilisation of ingested material.

Esomeprazole is a substituted benzimidazole prodrug. After oral absorption, it is distributed to the parietal cells via the bloodstream and accumulates in the acidic secretory canaliculi.

In this low-pH environment, esomeprazole is converted to its active sulphenamide form, which then forms a covalent disulphide bond with specific cysteine residues on the proton pump.

This binding is irreversible, rendering the enzyme permanently inactive. Acid secretion only resumes when new proton pumps are synthesised, which takes approximately 3 to 5 days.

This explains why the full acid-suppressing effect of esomeprazole builds over several days of regular dosing.

Esomeprazole is the S-enantiomer (optical isomer) of omeprazole. Compared with racemic omeprazole, esomeprazole undergoes less first-pass hepatic metabolism (via CYP2C19), resulting in higher and more predictable plasma concentrations.

This translates to slightly more consistent acid suppression, which may offer a clinical advantage in healing severe erosive oesophagitis, though for most patients with uncomplicated GORD, the practical difference between PPIs is small.

Clinical evidence and UK prescribing guidance

PPIs are the most effective class of acid-suppressing medication available, superior to H2 receptor antagonists (such as ranitidine and famotidine) in both symptom control and mucosal healing.

Esomeprazole has been studied in numerous large randomised controlled trials. Key evidence includes the following findings.

For erosive oesophagitis, esomeprazole 40 mg healed approximately 90% of cases at 8 weeks in clinical trials, compared with approximately 80% for omeprazole 20 mg.

For symptom relief in non-erosive GORD, esomeprazole 20 mg provides effective heartburn control in the majority of patients. For H.

pylori eradication, PPI-based triple therapy achieves eradication rates of approximately 80 to 90% when local antibiotic resistance rates are low.

For NSAID-associated ulcer prevention, esomeprazole 20 mg once daily significantly reduced the incidence of gastric and duodenal ulcers in at-risk patients (those over 60, those with previous ulcer history, or those taking concomitant aspirin or anticoagulants).

NICE guideline NG12 (suspected cancer: recognition and referral) advises urgent endoscopy referral for patients with dysphagia or for patients aged 55 and over with unexplained weight loss and upper abdominal pain, reflux, or dyspepsia.

This is to exclude oesophageal or gastric malignancy before attributing symptoms to benign GORD. PPIs should not be started empirically in patients with alarm features without appropriate investigation.

The British National Formulary (BNF) lists esomeprazole for GORD (with or without oesophagitis), peptic ulcer disease, H. pylori eradication, NSAID-associated ulcer treatment and prevention, and Zollinger-Ellison syndrome.

NICE guidance on prescribing PPIs emphasises using the lowest effective dose, reviewing treatment regularly, and considering stepping down or stopping in patients who have been symptom-free for a prolonged period.

Indications and dosage

Gastro-oesophageal reflux disease

For erosive reflux oesophagitis: 40 mg once daily for 4 weeks, extended to 8 weeks if not fully healed. Maintenance to prevent relapse: 20 mg once daily.

For symptomatic GORD without erosion: 20 mg once daily for up to 4 weeks.

On-demand use (taking the medicine only when symptoms occur) may be appropriate for patients with intermittent symptoms.

H. pylori eradication

Esomeprazole 20 mg twice daily in combination with two antibiotics for 7 days.

Standard regimens include esomeprazole plus amoxicillin 1 g twice daily and clarithromycin 500 mg twice daily, or esomeprazole plus metronidazole 400 mg twice daily and clarithromycin 500 mg twice daily.

Your prescriber will select the regimen based on local antibiotic resistance data and individual patient factors including allergy history.

NSAID-associated ulcers

For healing: 20 mg once daily for 4 to 8 weeks. For prevention in at-risk patients: 20 mg once daily for as long as NSAID therapy continues.

Administration advice

Take esomeprazole at least 30 minutes before food, ideally before breakfast. Swallow tablets or capsules whole with water. Do not crush or chew enteric-coated formulations.

Dispersible tablets or granules are available for patients who have difficulty swallowing; these can be dissolved in water and taken as a suspension.

Side effects of esomeprazole

Common side effects

The most frequently reported side effects include headache, abdominal pain, diarrhoea, constipation, flatulence and nausea. These are generally mild and affect 1 to 10% of patients. They usually resolve with continued treatment or after stopping the medicine.

Less common side effects

Uncommon side effects include dizziness, dry mouth, skin rash, peripheral oedema, blurred vision, insomnia, paraesthesia and taste disturbance. Rare effects include hepatitis, interstitial nephritis, blood disorders and severe skin reactions.

Long-term use considerations

The MHRA and NICE have highlighted that prolonged PPI use (typically beyond one year) may be associated with small increased risks of Clostridium difficile infection, community-acquired pneumonia, osteoporosis-related fractures (hip, wrist, spine), hypomagnesaemia, vitamin B12 deficiency and, in rare cases, subacute cutaneous lupus erythematosus (SCLE).

These risks are generally small in absolute terms, and the benefits of PPI therapy usually outweigh them when there is a clear indication.

However, they underscore the importance of using the lowest effective dose for the shortest necessary duration and reviewing long-term prescriptions regularly.

When to seek medical advice

Seek urgent medical advice if you develop difficulty swallowing, unexplained weight loss, persistent vomiting, vomiting blood, or black tarry stools, as these may indicate a serious condition requiring investigation.

Contact your GP if you experience muscle cramps, tremor or palpitations (which may suggest low magnesium), new skin rash in sun-exposed areas (possible SCLE), or any persistent or troublesome side effect.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Alarm symptoms

Do not take esomeprazole without medical assessment if you have alarm symptoms including dysphagia, odynophagia (painful swallowing), haematemesis, melaena, unexplained weight loss, new onset dyspepsia over the age of 55, or unexplained iron deficiency anaemia.

These features require prompt investigation to exclude malignancy or other serious pathology. PPIs can mask the symptoms of gastric cancer.

Drug interactions

Esomeprazole interacts with clopidogrel (reduced antiplatelet effect via CYP2C19 inhibition; avoid if possible), methotrexate (increased levels; consider stopping PPI during high-dose methotrexate), HIV protease inhibitors including atazanavir and nelfinavir (reduced absorption; concurrent use not recommended), and drugs whose absorption depends on gastric pH (reduced absorption of ketoconazole, itraconazole, erlotinib; increased absorption of digoxin).

Inform your prescriber of all medicines you are taking.

Rebound acid hypersecretion

Stopping a PPI after prolonged use may cause a temporary increase in acid production (rebound acid hypersecretion), which can produce reflux symptoms even in people who did not have GORD before starting the PPI.

This is one reason why many patients find it difficult to stop PPIs.

A gradual step-down approach (reducing the dose over 2 to 4 weeks or switching to alternate-day dosing before stopping) may help manage this effect.

How to get esomeprazole in the UK

Esomeprazole 20 mg is available from pharmacies without a prescription for adults with reflux symptoms lasting up to 2 weeks.

For longer courses, higher doses, or specific conditions such as peptic ulcer or H. pylori eradication, a prescription is required. Your GP can prescribe esomeprazole following clinical assessment.

Authorised online prescribers registered with the GPhC can also issue prescriptions after a structured consultation.

The NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales and Northern Ireland.

Lifestyle measures for GORD alongside esomeprazole

Medicines work best alongside appropriate lifestyle changes. Lose weight if you are overweight. Elevate the head of your bed by 10 to 20 cm to reduce nocturnal reflux.

Avoid large meals, particularly in the 3 hours before bedtime.

Limit foods and drinks that trigger your symptoms (common triggers include fatty food, chocolate, coffee, alcohol, citrus fruits and tomato-based sauces).

Stop smoking, as nicotine relaxes the lower oesophageal sphincter. Wear loose-fitting clothing and avoid bending or straining after meals.

When to review your treatment

If you have been taking esomeprazole for more than 8 weeks, discuss with your GP whether continued treatment is necessary.

Many patients with uncomplicated GORD can step down to a lower dose, switch to on-demand use, or try stopping the PPI altogether.

Your GP can help you manage any rebound symptoms during the step-down process. If symptoms recur, long-term low-dose maintenance may be appropriate.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Esomeprazole Gastro-resistant Tablets, Summary of Product Characteristics (EMC)
• Esomeprazole, British National Formulary (BNF)
• NICE CKS: GORD in adults
• NICE CKS: Dyspepsia, unidentified cause
• Esomeprazole, NHS
• MHRA Yellow Card Scheme